Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alzheimer Disease 2 Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

NCT01680588
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]NAV4694
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
7
States / cities
New Haven, Connecticut • Chicago, Illinois • Elk Grove Village, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jul 23, 2026, 6:06 AM EDT
Active, not recruiting Not applicable Interventional

Brain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention

NCT05027789
View directory record Official record
Conditions
Memory Disorders, Cognitive Impairment
Interventions
Self-Guided, Structured Group
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
65 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 23, 2026, 6:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Late Onset Alzheimer's Disease

NCT05010603
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood Draw, Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Genetic · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Miami, Florida • Aurora, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers

NCT05817643
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
BMS-984923
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Not applicable Interventional Results available

Communication Bridge 2

NCT03371706
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Communication Bridge™, Evidence-Based Impairment Focused
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jul 23, 2026, 6:06 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

NCT06808984
View directory record Official record
Conditions
Agitation, Alzheimer Disease
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
55 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
53
States / cities
Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 2 Interventional

Curcumin in Patients With Mild to Moderate Alzheimer's Disease

NCT00099710
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Curcumin C3 Complex
Dietary Supplement
Lead sponsor
John Douglas French Foundation
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

NCT05408780
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AC-OLE-01-VA
Drug
Lead sponsor
Cerecin
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Jul 23, 2026, 6:06 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

NCT04100889
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Not applicable Interventional

Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2

NCT03933696
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Type2 Diabetes
Interventions
Tailored Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Terminated Early Phase 1 Interventional

Brain Imaging in the Diabetes Prevention Program Outcomes Study

NCT03757910
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-MK-6240, 11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

NCT00117650
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis
Interventions
Ad2/HIF-1α/VP16, Saline (Placebo Control)
Biological · Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
40 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
35
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Not applicable Interventional Results available

Exercise and the Receptor for Advanced Glycation End Products (RAGE)

NCT03534687
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Aerobic Exercise
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Jul 23, 2026, 6:06 AM EDT
Recruiting Phase 2 Interventional

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

NCT07033494
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
MK-2214, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional

A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil

NCT00672945
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PRX-03140, Placebo
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • National City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2009 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 1 Interventional Results available

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

NCT03852901
View directory record Official record
Conditions
Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
Interventions
empagliflozin (Jardiance) 25 mg
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Jul 23, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

NCT03352557
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 23, 2026, 6:06 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug (SC), Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 2 Interventional Results available

Tau Screening Study in Subjects With Early Symptomatic AD

NCT03467477
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
9
States / cities
Irvine, California • Delray Beach, Florida • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Jul 23, 2026, 6:06 AM EDT
Active, not recruiting Phase 2 Interventional

Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation

NCT06691256
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
Interventions
HiDO-ALZ
Device
Lead sponsor
HiDO Technologies
Industry
Eligibility
65 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

NCT01795339
View directory record Official record
Conditions
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Jul 23, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

NCT06721156
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
MK-1167, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Irvine, California • Redlands, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 1 Interventional

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

NCT02502253
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
grape seed polyphenolic extract, resveratrol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 1Phase 2 Interventional

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

NCT03236792
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Ixazomib, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Jul 23, 2026, 6:06 AM EDT